Gene replacement therapy with onasemnogene abeparvovec in children with spinal muscular atrophy aged 24 months or younger and bodyweight up to 15 kg: an observational cohort study.
Lancet Child Adolesc Health
; 6(1): 17-27, 2022 01.
Article
in En
| MEDLINE
| ID: mdl-34756190
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Oligonucleotides
/
Body Weight
/
Muscular Atrophy, Spinal
/
Genetic Therapy
Type of study:
Clinical_trials
/
Etiology_studies
/
Guideline
/
Observational_studies
Limits:
Child, preschool
/
Female
/
Humans
/
Infant
/
Male
Country/Region as subject:
Europa
Language:
En
Journal:
Lancet Child Adolesc Health
Year:
2022
Document type:
Article
Affiliation country: